Flowchart of patients. by Seydou Goro (17847203)

“…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”

Baseline characteristics of patients. by Seydou Goro (17847203)

“…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”

Table_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Image_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_4_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Image_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_3_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Fig 1 - by Denise Wajnsztajn (3366902)

Characteristics of dexmedetomidine use. by Shi-Yuan Yu (17054536)

“…Forty-five percent of patients had ≥50% days of rousable sedation. …”

Baseline characteristics. by Shi-Yuan Yu (17054536)

“…Forty-five percent of patients had ≥50% days of rousable sedation. …”

Prevalence of noncommunicable diseases among women and men by division and survey round, Bangladesh 2004–2018. by Phuong Hong Nguyen (3240171)

Representation of market types (by distance method) and their mortalities. by Seydou Goro (17847203)

Data_Sheet_1_Catheter-Based Therapies Decrease Mortality in Patients With Intermediate and High-Risk Pulmonary Embolism: Evidence From Meta-Analysis of 65,589 Patients.DOCX by Arkadiusz Pietrasik (12879863)

“…</p>Objective<p>We conducted a systematic review with meta-analysis to compare the efficacy and safety of CDT and ST in intermediate-high and high-risk PE.…”

Fig 4 - by Denise Wajnsztajn (3366902)

Caregivers’ transcripts. by Maggie Nyirenda-Nyang’wa (14129602)

“…A total of 65 SSIs were conducted among caregivers (n = 60) and health care providers (n = 5). …”

Codebook. by Maggie Nyirenda-Nyang’wa (14129602)

“…A total of 65 SSIs were conducted among caregivers (n = 60) and health care providers (n = 5). …”

Health workers and caregivers’ transcripts. by Maggie Nyirenda-Nyang’wa (14129602)

“…A total of 65 SSIs were conducted among caregivers (n = 60) and health care providers (n = 5). …”

Recruitment of α5-GABA_ARs to PV-synapses contributes to wake-dependent enhancement of iLTP. by Kunwei Wu (725668)

“…(K) Representative PV-IPSC traces at indicated time points in (J). (L) L655,708 decreased the potentiation of PV-IPSC amplitude after NMDA application in wake and sleep-deprived mice (SD) but not sleep mice (<i>n</i> = 7–8, 2-way ANOVA, F (4, 38) = 4.234, <i>p</i> = 0.0062 with Sidak’s multiple comparison test, Sleep a versus Sleep b, <i>p</i> = 0.028; Sleep a versus Sleep c, <i>p</i> = 0.04; Wake a versus Wake b, <i>p</i> = 0.0014; Wake b versus Wake c, <i>p</i> = 0.023; Wake a versus Wake c, <i>p</i> = 0.0008; SD a versus SD b, <i>p</i> < 0.0001; SD b versus SD c, <i>p</i> = 0.0091; SD a versus SD c, <i>p</i> = 0.0002; Sleep b versus Wake b, <i>p</i> = 0.028; Sleep b versus SD b, <i>p</i> = 0.04). …”

Data_Sheet_1_Serious games and eating behaviors: A systematic review of the last 5 years (2018–2022).PDF by Pierpaolo Limone (10821258)